![]() |
|
|
Vol. 301, Issue 3, 945-952, June 2002
Department of Pharmacology, University of Michigan, Ann Arbor,
Michigan (C.S., U.M.K., P.F.H.); and Department of Physiology and
Pharmacology, University of Queensland, St. Lucia, Brisbane,
Queensland, Australia (L.M.N., E.M.J.G.)
Tamoxifen is primarily used in the treatment of breast cancer. It
has been approved as a chemopreventive agent for individuals at high
risk for this disease. Tamoxifen is metabolized to a number of
different products by cytochrome P450 enzymes. The effect of tamoxifen
on the enzymatic activity of bacterially expressed human cytochrome
CYP2B6 in a reconstituted system has been investigated. The
7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation
activity of purified CYP2B6 was inactivated by tamoxifen in a time- and concentration-dependent manner. Enzymatic activity was lost only in
samples that were incubated with both tamoxifen and NADPH. The
inactivation was characterized by a KI of
0.9 µM, a kinact of 0.02 min
1, and a t1/2 of 34 min.
The loss in the 7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation activity did not result in a similar
percentage loss in the reduced carbon monoxide spectrum, suggesting
that the heme moiety was not the major site of modification. The
activity of CYP2B6 was not recovered after removal of free tamoxifen
using spin column gel filtration. The loss in activity seemed to be due
to a modification of the CYP2B6 and not reductase because adding fresh
reductase back to the inactivated samples did not restore enzymatic
activity. A reconstituted system containing purified CYP2B6,
NADPH-reductase, and NADPH-generating system was found to catalyze
tamoxifen metabolism to 4-OH-tamoxifen, 4'-OH-tamoxifen, and
N-desmethyl-tamoxifen as analyzed by high-performance liquid chromatography analysis. Preliminary studies showed that tamoxifen had no effect on the activities of CYP1B1 and CYP3A4, whereas CYP2D6 and CYP2C9 exhibited a 25% loss in enzymatic activity.
This article has been cited by other articles:
![]() |
M. Rahman, S. F. Lax, C. H. Sutter, Q. T. Tran, G. L. Stevens, G. L. Emmert, J. Russo, R. J. Santen, and T. R. Sutter CYP1B1 Is Not a Major Determinant of the Disposition of Aromatase Inhibitors in Epithelial Cells of Invasive Ductal Carcinoma Drug Metab. Dispos., May 1, 2008; 36(5): 963 - 970. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Kharasch, D. Mitchell, and R. Coles Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) Activity J. Clin. Pharmacol., April 1, 2008; 48(4): 464 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E. A. Lien Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial Clin. Cancer Res., April 1, 2004; 10(7): 2336 - 2343. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. F. El-Rayes, S. Ali, L. K. Heilbrun, S. Lababidi, D. Bouwman, D. Visscher, and P. A. Philip Cytochrome P450 and Glutathione Transferase Expression in Human Breast Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1705 - 1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang, S. Faucette, T. Sueyoshi, R. Moore, S. Ferguson, M. Negishi, and E. L. LeCluyse A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression J. Biol. Chem., April 11, 2003; 278(16): 14146 - 14152. [Abstract] [Full Text] [PDF] |
||||